Biotech Daily

Friday October 23, 2026

Daily news on ASX-listed biotechnology companies

*** ASX FLAT, BIOTECH DOWN: IMMUTEP UP 5%; MICRO-X DOWN 9%**

*** BEDA OPENS ALSAN INVESTOR NETWORK**

*** DR BOREHAM'S CRUCIBLE: EMYRIA**

*** PROTEOMICS AUSTRALIA PROMARKER D, ESO LAUNCH**

*** PARADIGM CANCELS NOTES; CREDITORS MEETING; REPORTS, AGM**

*** DIMERIX: DMX-200 TARGET CCR2 'BIOLOGICALLY RELEVANT FOR FSGS'**

*** PERCHERON HMBD-002 READY FOR VANDERBILT BLOOD CANCER TRIAL**

*** BIOTRON RECEIVES $208k FEDERAL R&D TAX INCENTIVE**

*** RESONANCE REQUESTS 'RESULTS, PLACEMENT' TRADING HALT**

*** ISLAND 9m BOARD OPTIONS AGM**

*** AUDEARA 6m BOARD OPTIONS AGM**

*** MACH7 2.5m M-D RIGHTS, 60% DIRECTOR FEE HIKE AGM**

*** CLARITY 2.6m CHAIR, CEO OPTIONS AGM**

*** EMVISION 1.1m BOARD OPTIONS, 800k M-D RIGHTS AGM**

*** ECHO IQ 2m DIRECTOR OPTIONS AGM**

*** PINNACLE BELOW 5% OF COCHLEAR**

*** INOVIQ LOSES 10-YEAR CEO DR LEEARNE HINCH**

*** NOVA EYE LOSES 8-YEAR DIRECTOR MIKE SOUTHARD**

*** SKORIKOVA, DI PIETRO REPLACE PRESCIENT CO SEC LEYDIN**

MARKET REPORT

The Australian stock market edged up 0.02 percent on Friday October 23, 2026, with the ASX200 up 2.0 points to 8,795.2 points. Eight of the Biotech Daily Top 40 stocks were up, 22 fell, eight traded unchanged and two were untraded. All four Big Caps were up.

Immutep was the best, up 0.1 cents or 4.55 percent to 2.3 cents, with 2.6 million shares traded. Alcidion, Cochlear and Proteomics climbed more than four percent; Optiscan and Resmed were up more than three percent; Amplia, Aroa and Pro Medicus rose more than two percent; Racura was up 1.6 percent; with Clinuvel and CSL up less than one percent.

Micro-X led the falls, down 0.5 cents or 8.6 percent to 5.3 cents, with 854,487 shares traded. Artrya and Botanix lost more than seven percent; Clarity was down 6.3 percent; Syntara shed 5.0 percent; Dimerix and Emvision fell more than four percent; EBR, Imricor, Mesoblast, Nova Eye, Prescient and Telix were down three percent or more; 4D Medical, Actinogen and Imugene shed more than two percent; Neuren, Polynovo, Orthocell, Saluda and Starpharma were down more than one percent; with Avita down by 0.9 percent.

BRISBANE ECONOMIC DEVELOPMENT AGENCY (BEDA)

The Brisbane Economic Development Agency (BEDA) says it has launched an Australian Life Science Angels Network (ALSAN) investor community.

BEDA said the network would connect life sciences companies with investors “to back emerging health innovations and help ideas progress towards real-world impact”.

The organization said the network complemented its Medtech Initiative Global Accelerator, which had “helped more than 40 companies raise $391 million in capital and create more than 315 jobs since launching, strengthening Brisbane's pipeline of investment-ready health and life sciences businesses”.

BEDA said the member-led investor community would be part of Angel Loop, which had “already invested in 11 Medtech Initiative alumni, demonstrating growing investor confidence in Brisbane's health innovation sector and the opportunities emerging from its pipeline of high-potential companies”.

The organization said the national network was “open to both seasoned life sciences investors and the ‘bio-curious’, those interested in backing emerging health innovations, supported by a community of experienced investors and industry experts”.

BEDA said the network was launched at Ausbiotech International 2026, being held this week at Queensland’s Gold Coast Convention and Exhibition Centre.

BEDA chief executive officer Anthony Ryan said Brisbane had “the talent, research, and capability here, and the opportunity is to continue strengthening the capital and connections that help our innovators grow and compete globally, while delivering solutions that can improve lives”.

“Brisbane is already producing exciting health innovations and high-potential companies,” Mr Ryan said.

“We want to see more of them find the investment, support and expertise they need to scale from Brisbane and become global success stories,” Mr Ryan said.

“Access to capital is critical to making that happen, and ALSAN is another important piece of the puzzle, connecting Brisbane’s innovators with the investors, expertise and networks they need to grow,” Mr Ryan said.

Email hello@alsan.org.au for more information on the ALSAN network.

DR BOREHAM'S CRUCIBLE: EMYRIA

By TIM BOREHAM

ASX code: EMD

Share price: 3.9 cents; **Shares on issue:** 806,686,029; **Market cap:** $31.5 million

Chief executive officer: Greg Hutchinson

Board: Greg Hutchinson (executive chair), Dr Michael Winlo (executive director), Dr Karen Smith, Dr Mohit Kaushal, Prof Sir John Tooke (retires at the November 12 AGM)

Financials (year to June 30, 2026): operating revenue $4.05 million (up 191%), loss of $6.11 million ($3.14 million deficit previously), cash of $7.29 million (up 104%)

Identifiable major shareholders: Greg Hutchinson 5.29%, Dr S and P Washer and associates 5.425%, Craig Darby 2.96%, Mercator Shipwrights Pty Ltd 2.44%

When does a small ASX-listed biotech know that it's making a splash on the world stage? When it is invited to participate in a public US Food and Drug Administration exposition on a health topic of burning interest.

Thus, Emyria executive chair Greg Hutchinson last month made the pilgrimage to the FDA's Maryland spiritual headquarters, to front the agency's public hearing on "considerations for potential future therapeutic use of psychedelic drugs".

The hearing brought together regulators, Federal healthcare representatives, drug developers, healthcare providers and others "to consider practical issues associated with the potential future therapeutic use of psychedelic medicines". Mr Hutchinson says the FDA hearing validated Emyria's experience in treating patients in a regulated healthcare system.

While it's a minnow, Emyria was able to offer valuable insights given its unique position in the evolving sector. Courtesy of Australia's regulations, Emyria is apparently the world's biggest legal provider of commercial psychedelic-assisted therapies.

"As psychedelic medicines move toward broader adoption, the challenge is no longer just about drug development," he says. "It is about building the systems to deliver treatment safely, consistently and at scale."

Yes – the Kingswood

Emyria this month opened its fourth clinic under its Empax brand, at Matilda Private Hospital in the Western Sydney suburb of Kingswood.

This adds to the company's foundation Perth clinic and facilities in Brisbane and on Victoria's Mornington Peninsula.

Mr Hutchinson says the local Therapeutic Goods Administration “surprised almost everyone” when three years ago it allowed the use of psychedelic drug treatments in strictly controlled circumstances.

The agency ‘down-scheduled’ 3-4-methylene-dioxy-meth-amphetamine (MDMA, ‘molly’ or ‘ecstasy’) and psilocybin (‘magic mushrooms’) from a Schedule 9 prohibited substance, to a Schedule 8 (strictly) controlled drug.

This liberalization is confined to researching psilocybin for treatment-resistant depression (TRD) and MDMA for post-traumatic stress disorder (PTSD).

The reform opened the TGA’s authorized prescriber pathway, allowing qualified psychiatrists to prescribe the substances under strictly controlled conditions.

The authorized prescriber route is similar to the one available for medical cannabis, but with more arduous hurdles.

Ahead of the TGA changes effective from July 1 2023, Emyria acquired a trauma-focused multi-disciplinary psychiatry therapy clinic in Perth.

“This meant the psychiatrists working in the facility had the necessary level of supervision required,” Hutchinson says.

“We then set about creating a dedicated treatment facility to be able to treat patients with PTSD and treatment-resistant depression”.

Emyria by any other name

Emyria evolved from Emerald Clinics, which ran medical cannabis facilities.

Backed by well-known biotech figure Dr Stewart Washer, Emerald listed on February 12, 2020, having raised $6 million at 20 cents apiece.

Noting a “chronic oversupply” of cannabis, Emyria turned to a “scalable, evidence-based” clinical model for MDMA, in exclusive partnership with Mind Medicine Australia.

The company opened its first (Perth) clinic in November 2023.

Emyria since has won Medibank Private health insurance cover. It also has an agreement with Avive Health to establish Empax clinics in all current and future Avive hospital sites.

Emyria hired Mr Hutchinson in late 2023 for his experience in acquiring, building, managing and divesting clinics across multiple medical disciplines.

For 15 years he headed Sonic Health Plus, the pathology group’s clinic chain.

Meanwhile, at the company’s upcoming November 12 AGM shareholders will vote on changing the company’s moniker to Empax Group.

Strict controls

We must stress the local psychedelics regime is not intended as a wild west ‘free for all’. Clinical protocols must be approved by an ethics committee and the dosing must occur under direct supervision in an approved, controlled hospital or day clinic.

Providers are banned from advertising or promoting that they prescribe or supply psychedelic-assisted therapies.

And the treatments are not intended as first line therapies.

“The definition of treatment-resistant is that you've tried and failed on two different therapies or drugs,” Mr Hutchinson says.

“We don't see patients that early. We tend to see them much later in their journey, but I think over time we will see them earlier.”

How the treatment process works

The drugs must be delivered alongside 90 hours of therapy.

“Patients can be referred from a [general practitioner] but more likely by an external psychiatrist or therapist,” Mr Hutchinson says.

The patients are screened with a nurse or therapist and then with the psychiatrist authorized prescriber.

“The screening process takes six to 12 weeks,” Mr Hutchinson says. “In that period, they need to be tapered off anti-depressants to avoid any unwanted interactions.”

Mr Hutchinson believes 80 percent of patients might be appropriate for the program.

The first dosing entails an eight-hour session, with two therapists always required to be present.

After eight hours, the patient is released into the care of a support person. They can’t drive for 48 hours. The next day, the patient has a consultation to talk through the experience. The patients then undergo two more “integration sessions” over the next fortnight.

Cost-benefit analysis convinces Medibank

The treatment costs about $30,000 for a full round of PTSD therapy and $20,000 for treatment-resistant depression (TRD).

That sounds a lot, but bear in mind more severe patients may have been hospitalized multiple times annually. This could cost the health system many times more.

Initially, Empax patients bore the full cost of the treatment.

“Because of their mental health issues many … hadn’t worked for a prolonged period,” Mr Hutchinson says. “Some had to dip into their sofa and others had family help to do so.”

Emyria’s commercial breakthrough moment came in June last year when Medibank Private agreed to fund the procedures - with no gap payment.

Of course, the health insurer is not a charity and saw the health economics stack up.

The fund recognized that “people just get on this merry-go-round, and they never get off” Mr Hutchinson says.

Meanwhile, other major private health insurers have taken a ‘wait-and-see approach’, although some have granted individual ad-hoc approvals.

‘Hospital-as-a-hotel’ model

Empax has treated around 130 patients, mainly Medicare funded.

“Our strategy has been to build out as many clinics as we possibly can as fast as we can,” Mr Hutchinson says.

Emyria bases its clinics around existing hospital infrastructure for two key reasons.

Medibank will only reimburse in a hospital context, while the “hotel like” model is capital-light. A new clinic costs around $250,000 to set up.

“We’re effectively renting beds in hospital; most of the cost is recruiting and training of therapists and clinicians,” Mr Hutchinson says. “It gives us a really fast and effective way of rolling out clinics across the country at scale. The psychiatrists, the therapists and the patients are there already”.

Meanwhile, the hospitals benefit from more admissions.

Room for more in the clinic

Earlier this year, the TGA updated its recommendations about who can – and should be - present during psychedelic-assisted therapy sessions.

The attendees must include a clinical psychologist or doctor. But participation expands to other suitable qualified parties such as mental health nurses and occupational therapists.

Crucially, the participants are vetted by the authorized prescriber, but this psychiatrist does not have to always be in the room.

“As such they can oversee multiple patients simultaneously,” Mr Hutchinson says.

Typically, an Empax clinic does four sessions a day, so that requires eight therapists overseen by one psychiatrist.

Mr Hutchinson says Emyria's capacity is limited by the availability of clinical psychologists (the psychiatrists are part-time contractors).

"They're the most expensive and the most difficult [professionals] to come by," he says.

"That's been our biggest bottleneck in terms of getting patients through the system."

Expanded indications?

Mr Hutchinson says psychedelic-assisted therapy could be most relevant for mental health related workers' compensation scenarios, especially for PTSD and TRD.

He notes that 14,000 New South Wales police officers are off work for mental health reasons.

"With the first responders, you can understand that," he says.

"But doctors and teachers also are subject to some pretty nasty things these days."

In the US, more veterans have died from suicide than have died from combat since World War Two: 120,000 over the last two decades, according to the White House.

Mr Hutchinson believes Emyria could sustain 20 to 30 clinics Empax nationally, for just PTSD and TRD.

But he notes that trials are taking place for other indications including addictions (smoking cessation) and anxiety.

"If the indications expand, I can see us running 50 to 70 clinics," he says.

Beyond hospitals, Mr Hutchinson envisages veterans-only or eating disorders and drug and alcohol abuse clinics.

Finances and performance

Emyria generated $4.05 million from its treatment activities in the year to June 30 2026, up 190.6 percent. The company also pocketed a $191,000 Federal Research and Development Tax Incentive, having expended $531,000 on research and development during the period (down 13 percent).

The company lost a net $6.11 million, compared to a $3.14 million deficit a year earlier.

At June 30, Emyria had $7.29 million of cash in the bank, having raised $8 million, last November, in an institutional placement at six cents per share, a nine percent discount.

Emyria doesn't disclose its gross margin, but Mr Hutchinson says a clinic needs to administer 15-20 dosings a month to break even.

The company said its Perth clinic, its most mature, achieved 31 dosings in June and has been profitable on a standalone basis for some time.

The clinic is capable of 80 dosings per month.

“It takes us about nine to 12 months to get a clinic up to profitability typically,” Mr Hutchinson says.

Over the last 12 months, Emyria shares have tripped between their all-time low of 3.6 cents in mid-March this year and 7.4 cents in mid-November last year. The shares peaked at 45.7 cents in late November 2021.

Dr Washer and his associates remain Emyria’s biggest shareholder, with an 8.25 percent stake.

Dr Boreham’s diagnosis:

While the jury is out on the efficacy of mind-altering drugs, the interest in the sector has been, well, mind blowing.

In April, the President Donald Trump administration introduced reforms to facilitate psychedelic drug development.

Aimed especially at treating veterans, these include $US50 million for state-federal mental illness programs and streamlined FDA procedures.

Mr Hutchinson says Mr Trump’s executive order was “massive” in terms of fast-tracking psychedelics research, especially for PTSD.

While pollies talk, money talks louder. The world’s biggest drug company, Eli Lilly, proposes to buy Atai Beckley for up to $US3.8 billion as it pursues psychedelic-based treatments for TRD and social anxiety disorder.

This was hard on the heels of Abbvie's up to US$1.2 billion for Gilgamesh Pharmaceuticals.

While no regulator has approved a psychedelic therapy, the sector awaits a potential breakthrough: the FDA is mulling Compass Pathways’ fast-tracked marketing application for its psilocybin-based TRD candidate.

Approval or not, the demand big picture remains intact.

“Mental health is overtaking heart disease and cancer now as the biggest cause of disability in the world,” Mr Hutchinson says.

Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. Rather than magic mushrooms, he expects his trip of a lifetime to entail Rome, London, Paris and New York

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it will begin Australian commercialization of its Promarker D and Promarker Eso blood tests with Healius Ltd on Monday, October 26, 2026.

In July, Proteomics said it had an “exclusive pathology distribution agreement with Healius … for all Promarker tests”; and last month, said it began a “controlled market release” in Western Australia and the Northern Territory (BD: Jul 22, Sep 14, 2026).

At the time, the company said Australian Promarker D pricing was set at $495 for risk assessment for diabetic kidney disease up-to four years before clinical symptoms and $997 for Promarker Eso, which “assists in ruling out oesophageal cancer in patients with chronic reflux”; with the tests available initially on a private-pay basis.

Today, Proteomics said field sales teams had completed training on the Promarker D and Promarker Eso blood tests, including their intended clinical uses and the processes for accessing the tests.

The company said, that with Healius, it agreed joint sales and marketing plans to build clinician awareness, provide education and support appropriate referrals and access.

Proteomics said it would continue to perform laboratory testing in its [National Association of Testing Authorities] accredited facility, and provide clinical reporting, scientific and medical support, and quality and regulatory compliance.

Proteomics managing-director David Morris said the national rollout was “a significant milestone in bringing our Promarker portfolio to Australian clinicians and patients”.

Proteomics was up half a cent or 4.35 percent to 12 cents.

PARADIGM BIOPHARMACEUTICALS

Paradigm says it will redeem and cancel further Obsidian convertible notes, apply for a creditors’ meeting extension and delay its financial reports and investor meeting.

Paradigm said it had agreed with Obsidian Global GP LLC to pay $US348,900 ($A500,000) to redeem and cancel a further 290,993 convertible notes and that 2,834,715 convertible notes remained outstanding.

Last month, the company halted its 538-patient, phase III trial of injectable pentosan polysulfate sodium (PPS), or Zilosul, for knee osteoarthritis, citing the data safety monitoring board finding that the interim efficacy result “did not reach the pre-specified threshold required for the study to continue” (BD: Sep 23, 2026).

Later, Paradigm said it would return $US2 million to Obsidian Global GP and cancel the 2,000,000 convertible notes issued and had appointed FTI Consulting as its voluntary administrator (BD: Sep 24, 30, 2026).

Today, FTI said it had applied to the Supreme Court of Western Australia to have the convening period for the second meeting of creditors extended for up-to three months.

The administrators said the extension provided for assessment of “the board-led recapitalization proposal, progressing proposals from the interested parties during the sale process” completing investigations and obtaining an independent analysis of the results.

Paradigm said it would rely on sections 8 and 9 of the Australian Securities and Investment Commission (ASIC) Corporations Instrument 2025/584 which provided for the deferral of its financial reporting and annual general meeting obligations.

The company said it did not have to comply with the requirements of the Act in relation to the financial year or half-year, “where the requirement would otherwise have arisen within 24 months after the appointment of the administrators”.

Paradigm said it would hold an annual general meeting within two months after the end of the deferral period at which it would lay out all outstanding financial reports.

Paradigm was in a suspension and last traded at 24.5 cents.

DIMERIX

Dimerix says a 261-patient study shows c-c chemokine receptor type 2 (CCR2) “is a biologically relevant therapeutic target for focal segmental glomerulo-sclerosis (FSGS)”.
Dimerix said it funded the independent study, designed to determine whether CCR2 activation was linked to biomarkers associated with kidney outcomes in FSGS.
Last week, the company said that 100 of 333 patients had completed the two-year treatment period in its phase III trial of DMX-200 in focal segmental glomerulo-sclerosis kidney disease (BD: Oct 16, 2026).
Today, Dimerix said the findings “supported the inflammatory mechanism-of-action of DXM-200, which targets CCR2 in FSGS”.
The company said the results showed “that activation of the MCP-1/CCR2 inflammatory pathway is associated with disease progression and poorer outcomes in patients with FSGS”.
Dimerix said the study, titled ‘Intrarenal CCL2 and CCR2 Activation Profiles Are Linked to Non-invasive Urinary Biomarkers Associated with Outcomes in Patients with FSGS’ was presented by the University of Michigan’s Dr Sean Eddy at the American Society of Nephrology Kidney Week held in Denver Colorado from October 21 to 25, 2026.
The company said “taken together, the independent findings and … phase II biomarker data provide converging evidence that DMX-200 targets a pathway associated with disease progression in FSGS”.
Dimerix managing-director Dr Nina Webster said “together, these data further strengthen the scientific rationale for targeting CCR2 in FSGS as we continue progressing our fully recruited ‘Action3’ phase III study.”
Dimerix fell one cent or 4.9 percent to 19.5 cents with 2.2 million shares traded.

PERCHERON THERAPEUTICS (FORMERLY ANTISENSE THERAPEUTICS)

Percheron says it has completed HMBD-002 drug product manufacture to be used in an investigator-sponsored study for blood cancer with Vanderbilt Health.
Last year, Percheron said it had licenced Singapore’s Hummingbird Bioscience’s HMBD-002 for cancer (BD: Jun 26, 2025).
Earlier this year, the company said with the Nashville, Tennessee-based Vanderbilt Health it would conduct an investigator-sponsored 38-patient trial of HMBD-002 in acute myeloid leukaemia and myelo-dysplastic syndrome (BD: Aug 28, 2026).
Today, Percheron said that under its licencing agreement, Hummingbird Bioscience was responsible for the manufacture of one batch of drug substance for use in future clinical trials.
The company said it was “intimately involved in the campaign as observers, providing the company with invaluable experience and insight into the specific aspects of HMBD-002 manufacture” and that future batches would be its responsibility.
Percheron said that once US Food and Drug Administration regulatory approval was received to begin the Vanderbilt Health study, the material would be able to be administered to patients in combination with standard-of-care.
The company said that start-up activities for the trial were expected in 2026 with recruitment by July 2027.
Percheron managing-director Dr Michael Baker said it was “excellent to tick off another milestone that brings us one step closer to generating clinical data for HMBD-002”.
“Manufacturing of biologics like HMBD-002 is complex and we look forward to getting the study with Vanderbilt up and running”, Dr Baker said.
Percheron fell 0.1 cents or 25 percent to 0.3 cents with 1.9 million shares traded.

BIOTRON

Biotron says it has received a further $208,463 from the Australian Taxation Office (ATO) under the Federal Government's Research and Development Tax Incentive program.
Biotron said the additional incentive related to an amended assessment of its research and development expenditure for the year to June 30, 2024, taking the total received for that period to about $2.022 million.
The company said the funding would be used to progress its development programs.
In 2024, Biotron said it received $1,814,495 from the ATO under the Federal Government's Research and Development Tax Incentive program (BD: Oct 14, 2024).
Biotron was unchanged at 0.2 cents.

RESONANCE HEALTH

Resonance has requested a trading halt pending an announcement regarding "the preliminary results of its liver fibrosis … trial and a placement".
Trading will resume on October 27, 2026, or on an earlier announcement.
Resonance was untraded at 8.2 cents.

ISLAND PHARMACEUTICALS

Island says its annual general meeting will vote to issue 9,000,000 options to managing-director Dr David Foster, chair Jason Carroll and director Chris Ntoumenopoulos.
Island said the options were exercisable at 55 cents each within five years and would vest on regulatory and commercial milestones.
The company said the options were in addition to Dr Foster's $400,000 yearly pay, Mr Ntoumenopoulos' $144,000 annual salary and Mr Carroll's $100,000 fees.
Island said shareholders would vote to adopt the remuneration report, re-elect Mr Ntoumenopoulos as a director, approve the increased placement capacity, ratify the issue of broker options, adopt the new employee incentive plan and a Corporations Act sub-section 195(4) approval.
The meeting will be held at Level 5, 126 Phillip Street, Sydney on November 24, 2026 at 1pm (AEDT).
Island was up half a cent or 1.6 percent to 32.5 cents.

AUDEARA

Audeara says its annual general meeting will vote to issue 6,000,000 options to chair David Trimboli, managing-director Dr James Fielding and executive director Bill Peng.
Audeara said the meeting would vote to issue Mr Trimboli 1,500,000 options, Mr Fielding 2,500,000 options and Mr Peng 2,000,000 options, exercisable at five cents each within two years from the issue date as part of their incentives.
The company said the options were in addition to Mr Trimboli's $50,000 fees, Dr Fielding's $268,800 annual salary and Mr Peng's $246,400 yearly pay.
Audeara said investors would vote to adopt the remuneration report, re-elect David Trimboli as a director, approve the 10 percent placement capacity, issue shares in lieu of director fees, renew the employee incentive plan, ratify the prior issue of placement shares and options as well as approve director participation in the placement.
The meeting will be held at Grant Thornton, King George Central, Level 18, 145 Ann Street, Brisbane on November 24, 2026 at 11am (AEDT).
Audeara was untraded at 2.4 cents.

MACH7 TECHNOLOGIES

Mach7 says investors will vote to issue managing-director Teri Thomas 2,508,044 performance rights and increase the director fee pool by 60 percent to $800,000.
Mach7 said its annual general meeting would vote to issue Ms Thomas the rights which would vest on 'total shareholder return' related milestones, expiring on December 31, 2029 and were in addition to Ms Thomas' $665,000 fixed annual remuneration.
The company said the fee pool increase provided flexibility for additional North American and Asia-Pacific appointments, director attraction and retention, to reflect market competitiveness and its practice "of not issuing equity options to non-executive directors".
Mach7 said investors would vote on the remuneration report and to re-elect directors Robert Bazzani.
The meeting will be held online on November 24, 2026 at 10am (AEDT).
Mach7 was unchanged at 24 cents.

CLARITY PHARMACEUTICALS

Clarity says investors will vote to issue 2,628,866 options to executive chair Dr Alan Taylor and chief executive officer Michelle Parker and increase the director fee pool.
Clarity said its annual general meeting would vote to issue Dr Taylor 1,871,097 options and Ms Parker 757,769 options, exercisable at $2.031 each by July 1, 2031 and vesting on 'total shareholder return' related performance milestones.
The company said the options were in addition to Dr Taylor's $1,070,000 yearly pay and Ms Parker's $606,670 annual salary.
Clarity said the meeting would vote to increase the non-executive director feel pool by 28.6 percent from $700,000 to $900,000, to adopt the remuneration report, elect Dr Taylor and Allison Rossiter as directors and amend the equity incentive plan.
The meeting will be held at the Ground Floor Seminar Room of the National Innovation Centre, 4 Cornwallis Street, Sydney on November 25, 2026 at 10am (AEDT).
Clarity fell 10.5 cents or 6.3 percent to $1.57 with 5.9 million shares traded.

EMVISION MEDICAL DEVICES

Emvision says investors will vote to issue 400,000 options and 800,000 performance rights to managing-director Scott Kirkland, as well as 700,000 options to three directors.
Emvision said its annual general meeting would vote to issue Mr Kirkland the performance rights for no consideration and at no exercise price, subject to clinical and regulatory-related performance milestones.
The company said 200,000 of Mr Kirkland's options were exercisable at $2.40 by June 30, 2030, with the remaining 200,000 exercisable at $2.70 by June 30, 2031.
Emvision said the meeting would vote to issue 300,000 options to director John Keep and 200,000 options, each, to directors Philip Dubois and Tony Keane, exercisable at $2.70 by June 30, 2031.
The company said the incentives were in addition to Mr Kirkland's $400,000 base salary, Mr Keeps $98,325 yearly pay and Mr Keane and Mr Dubois' $56,925 fees.
Emvision said shareholders would vote to adopt the remuneration report, re-elect Mr Keep and Mr Keane as directors as well as approve the employee incentive plan and the 10 percent placement capacity.
The meeting will be held at Suite 4.01, 65 Epping Road, Macquarie Park, New South Wales on November 24, 2026 at 2pm (AEDT).
Emvision fell 6.5 cents or 4.3 percent to $1.46.

ECHO IQ

Echo IQ says its annual general meeting will issue 2,000,000 options to recently appointed director Scott Wilkin.
Last month, Echo IQ said it appointed Mr Wilkin as a director (BD: Sep 1, 2026).
Today, the company said Mr Wilkin's options were exercisable at $1.24 each within three years and were in addition to his $US96,000 ($A137,000) yearly fees.
Echo IQ said shareholders would vote to adopt the remuneration report, elect Mr Wilkin, Kenneth Nelson and Andrew Grover as directors, renew the partial takeover provisions, enable the issue of equity incentives under the employee incentive scheme and ratify the issue of placement shares.
The meeting will be held at Level 8, 1 O'Connell Street, Sydney on November 24, 2026 at 1pm (AEDT).
Echo IQ fell 1.5 cents or 3.3 percent to 44 cents with 5.8 million shares traded.

COCHLEAR

Brisbane's Pinnacle Investment Management Group Ltd says it has ceased its substantial shareholding in Cochlear.
Pinnacle said that it bought, sold and transferred shares between September 1 and October 20, 2026, with the single largest sale 184,311 shares on October 20 for $25,182,418, or $136.63 a share.
Cochlear was up $6.22 or 4.4 percent to $146.81 with 672,086 shares traded.

INOVIQ (FORMERLY BARD1 LIFESCIENCES)

Inoviq says 10-year chief executive officer Dr Leearne Hinch has mutually agreed with the board to step down, effective from October 27, 2026.
In 2016, the then Bard1 said that it had appointed Dr Hinch as its chief executive officer (BD: Nov 3, 2026).
Today, the company said chair Peter Gunzburg would assume the role of executive chair "on an interim basis receiving no additional remuneration, while the company conducts an executive search for a new chief executive officer".
Inoviq will advise the market of an appointment in due course.
Mr Gunzburg said "over the past 10 years, Dr Hinch has made a significant contribution to Inoviq's development".
"Under her leadership, the business has evolved from a single asset early-stage technology, into a company with two products in market, two products in later stage development and one in early development," Mr Gunzburg said.
"The board remain confident in the foundations established for Inoviq's next phase and thanks Dr Hinch for her leadership, commitment and valuable contributions," Mr Gunzburg said.
Inoviq was unchanged at 13.5 cents.

NOVA EYE MEDICAL

Nova Eye says Mike Southard has resigned as an executive director, effective from today, having served for eight years.
Nova Eye said it would "like to acknowledge Mr Southard's significant contribution … and thank him for his commitment, counsel and support of the company over many years".
Nova Eye fell half a cent or 3.2 percent to 15 cents.

PRESCIENT THERAPEUTICS

Prescient says it has appointed Mariia Skorikova and Tony Di Pietro as joint company secretaries, effective from today, replacing Melanie Leydin.

Prescient said Ms Skorikova had more than nine years of experience advising ASX-listed companies and Mr Di Pietro had more than 20 years of corporate and governance experience in Australia and the UK.

Prescient fell 0.2 cents or 3.6 percent to 5.4 cents with 1.2 million shares traded.